Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/02/26 00:15:07」(JST)

wiki en

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity.^[1] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.^[2] It was later approved in the European Union in the October of 2005. Complete responses have been achieved with this medication.

It is marketed in the US as Arranon and as Atriance in the EU by Novartis.^[3]

References

^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.
^ Cohen, M. H.; Johnson, J. R.; Justice, R; Pazdur, R (2008). "FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.
^ http://www.novartisoncology.com/products/atriance.jsp

Template:Novartis

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非プラチナ製剤ベースの癌化学療法の神経学的合併症の概要 overview of neurologic complications of non platinum cancer chemotherapy
2. 成人における再発性および難治性の急性リンパ芽球性白血病の治療 treatment of relapsed or refractory acute lymphoblastic leukemia in adults
3. 小児や青年の急性リンパ芽球性白血病の治療の概要 overview of the treatment of acute lymphoblastic leukemia in children and adolescents
4. 成人におけるフィラデルフィア染色体陰性急性リンパ芽球性白血病に対する導入療法 induction therapy for philadelphia chromosome negative acute lymphoblastic leukemia in adults
5. T細胞性前リンパ性白血病の治療 treatment of t cell prolymphocytic leukemia

English Journal

Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.

Nishijima TF1, Shea TC1, Wood WA1, Voorhees PM1, Jamieson K1.
Leukemia & lymphoma.Leuk Lymphoma.2015 Oct 8:1-4. [Epub ahead of print]
PMID 26293208

Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.

Luskin MR1, Ganetsky A2, Landsburg DJ1, Loren AW1, Porter DL1, Nasta SD1, Svoboda J1, Luger SM1, Frey NV3.
British journal of haematology.Br J Haematol.2015 Sep 25. doi: 10.1111/bjh.13771. [Epub ahead of print]
PMID 26403537

Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future.

Burke MP, Borland KM, Litosh VA1.
Current topics in medicinal chemistry.Curr Top Med Chem.2015 Sep 15. [Epub ahead of print]
Nucleoside and nucleobase antimetabolites have substantially impacted treatment of cancer and infections. Their close resemblance to natural analogs gives them the power to interfere with a variety of intracellular targets, which on one hand gives them high potency, but on the other hand incurs seve
PMID 26369814

Japanese Journal

SYNTHESIS OF NELARABINE WITH PURE β-ANOMER THROUGH LATE-STAGE C-H NITRATION/NITRO-REDUCTION

Heterocycles : an international journal for reviews and communications in heterocyclic chemistry 91(12), 2386-2393, 2015-12-01
NAID 40020709554

ALLに対するネララビン (特集急性リンパ性白血病(ALL))

血液内科 68(2), 183-188, 2014-02
NAID 40020006819

Nelarabine resistance of childhood T-cell lymphoblastic leukemia/lymphoma cells

The Kitakanto medical journla 63(1), 99-100, 2013-02-01
NAID 120005231540

Related Pictures

★リンクテーブル★

リンク元

「ネララビン」

Nelarabine
Systematic (IUPAC) name
	(2R,3S,4S,5R)-2-(2-amino-6-methoxy-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Clinical data
AHFS/Drugs.com	monograph
Licence data	EU EMA: Atriance; US FDA: Nelarabine;
Pregnancy; category	US: D (Evidence of risk); ;
Legal status	US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	<25%
Metabolism	By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Biological half-life	30 minutes (nelarabine); 3 hours (ara-G)
Excretion	Renal
Identifiers
CAS Number	121032-29-9
ATC code	L01BB07
PubChem	CID 3011155
IUPHAR/BPS	7090
DrugBank	DB01280
ChemSpider	2280207
UNII	60158CV180
KEGG	D05134
ChEMBL	CHEMBL1201112
Chemical data
Formula	C11H15N5O5
Molar mass	297.268 g/mol
	SMILES n2c1c(nc(nc1OC)N)n(c2)[C@@H]3O[C@@H]([C@@H](O)[C@@H]3O)CO ;
	InChI InChI=1S/C11H15N5O5/c1-20-9-5-8(14-11(12)15-9)16(3-13-5)10-7(19)6(18)4(2-17)21-10/h3-4,6-7,10,17-19H,2H2,1H3,(H2,12,14,15)/t4-,6-,7+,10-/m1/s1 ; Key:IXOXBSCIXZEQEQ-UHTZMRCNSA-N ;
(what is this?) (verify)

　　[★]

英: nelarabine
商: アラノンジー
関: 代謝拮抗剤

[1] "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015.

[Example2006a-2] Cohen, M. H.; Johnson, J. R.; Justice, R; Pazdur, R (2008). "FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926.

[3] ttp://www.novartisoncology.com/products/atriance.jsp

匿名

検索

案内

案内

nelarabine